Introduction {#Sec1}
============

Hypertension, an important risk factor for cardiovascular diseases (CVDs), affected an estimated one billion people worldwide in 2000 \[[@CR1], [@CR2]\]. This number is expected to rise to 1.56 billion by 2025 \[[@CR1]\]. In China, hypertension is the leading preventable risk factor for premature mortality \[[@CR3]\]. The majority of cardiovascular (CV) deaths in China were attributed to hypertension (2.11 million) in 2005 \[[@CR3]\]. The China National Nutrition and Health Survey findings indicated that nearly 0.2 billion (18%) adults in 2002 had hypertension and only 6.1% of them achieved blood pressure (BP) control \[[@CR4]\]. In 2010, a survey conducted among Chinese adults aged ≥18 years revealed that the prevalence of hypertension was 33.5% \[[@CR5]\].

According to the Chinese guidelines (2010) for the management of hypertension, a reduction in systolic BP (SBP) and diastolic BP (DBP) less than 140/90 mmHg in all hypertensive patients, and less than 130/80 mmHg in patients with concomitant diabetes or chronic kidney disease (CKD) is essential to reduce the risk of CV mortality \[[@CR6]\]. However, evidence from a previous study suggests that only a small proportion of the hypertensive population in China receives adequate treatment or achieves effective BP control \[[@CR7]\].

Single-drug therapy or monotherapy is the preferred way to initiate hypertension treatment, but BP goals (\<140/90 mmHg) cannot always be achieved with single-drug therapy in patients who require strong BP reductions \[[@CR8], [@CR9]\]. It has been proposed that in high-risk hypertensive patients who require a rapid and pronounced BP control, single-pill combination (SPC) or fixed-dose combination can be beneficial as a first-line therapy \[[@CR10]\]. SPCs offer several advantages such as improved efficacy, reduced adverse events (AEs), and improved patient compliance compared with monotherapy \[[@CR8]\]. Safe and effective combination of two or more drug classes is recommended for the majority of patients with hypertension to achieve their BP goal, which may translate into reduced risk of CV outcomes \[[@CR8]--[@CR14]\]. The 2013 European Society of Hypertension/European Society of Cardiology Guidelines for the management of arterial hypertension recommend the initiation of hypertension treatment with a combination of two drugs from different classes in patients with stage 2 hypertension (SBP ≥160 mmHg or DBP ≥100 mmHg) \[[@CR15]\]. Moreover, use of an antihypertensive drug combination in a single pill may further enhance BP control by reducing pill burden and enhancing compliance \[[@CR8], [@CR16]\].

Amlodipine (Aml) and valsartan (Val) are widely used antihypertensive drugs that have also been established to improve CV/renal outcomes \[[@CR17], [@CR18]\]. The combination of Val and Aml has shown an additive BP-lowering effect and minimal AEs in adult patients with mild-to-moderate hypertension compared to individual monotherapies \[[@CR13], [@CR14], [@CR19]\]. The efficacy and safety of this combination have also been demonstrated in the Chinese population through randomized controlled clinical trials \[[@CR20]--[@CR22]\]. Two of these studies evaluated SPC therapy and showed that it provided better outcomes in terms of efficacy, safety, and tolerability in Chinese patients compared with monotherapy \[[@CR20], [@CR21]\]. However, the effectiveness of Val/Aml SPC therapy has not been evaluated in real-world conditions in China. The present observational study was conducted to evaluate the effectiveness and safety of the Val (80 mg) and Aml (5 mg) SPC therapy on BP control at week 8 in a population of Chinese patients with uncontrolled BP on antihypertensive monotherapy in a real-life practice setting.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This was a multicenter, post-marketing, prospective observational study enrolled adult patients with essential hypertension, whose BP was not adequately controlled by monotherapy. Patients from 238 regional centers across 29 provinces of China were enrolled from October 12, 2010 to February 20, 2012. The Val/Aml (80/5 mg) SPC once-daily dosing was prescribed to the patients instead of the previous antihypertensive drugs. The treatment was in compliance with the routine clinical outpatient practice in China. The duration of the study was 8 weeks with a follow-up at every 4 weeks. If a patient did not achieve BP control at the end of 4 weeks, an additional antihypertensive agent could be added.

Study Population {#Sec4}
----------------

The study population included adult Chinese patients with essential hypertension \[(mean sitting SBP (MSSBP) ≥140 mmHg (≥130 mmHg for diabetes or CKD) and/or mean sitting DBP (MSDBP) ≥90 mmHg) (≥80 mmHg for diabetes or CKD)\], whose BP was not adequately controlled by monotherapy as mentioned in the Val/Aml package insert approved by the State Food and Drug Administration.

Patients were selected based on the following inclusion criteria: male or female aged ≥18 years with essential hypertension; on oral antihypertensive monotherapy (angiotensin-converting enzyme inhibitors (ACEIs), angiotensin-II receptor blockers (ARBs), calcium channel blockers (CCBs), diuretics, or β-blockers); MSSBP ≥140 mmHg and/or MSDBP ≥90 mmHg; with diabetes or CKD, MSSBP ≥130 mmHg and/or MSDBP ≥80 mmHg. Patients were prescribed the Val/Aml SPC based on the clinical judgment of the investigators according to the patient's condition and taking into consideration the package insert; signed informed consent was obtained for all patients. The exclusion criteria included women who were pregnant or lactating and or of child-bearing potential without adequate contraception measures, and or any other conditions which precluded administration of the drug based on the investigator's discretion.

Patient demographics, history of hypertension, past medical history and present complications, BP measure, present monotherapy, and the reason for switching medication were recorded for all the participants during the initial visit.

The study was conducted in accordance with the International Conference on Harmonization-Good Clinical Practice (ICH-GCP) and applicable local regulations in China. The study received approval from the Ethical Review Committee of The First Hospital of Harbin Medical University. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from all patients for being included in the study.

Efficacy Assessments {#Sec5}
--------------------

The primary efficacy variable of the study included changes in MSSBP and MSDBP from baseline to week 8 (end point). The secondary efficacy variable of the study included BP control rate and response rate (defined as the percentage of patients achieving MSSBP \<140 mmHg or MSSBP reduction ≥20 mmHg from baseline; MSDBP \<90 mmHg or MSDBP reduction ≥10 mmHg from baseline) at week 4 and 8. A subgroup analysis of the reduction in MSSBP and MSDBP values from baseline was performed at week 8 based on age (\<65, 65--\<80, ≥80), baseline SBP (\<140, 140--159, 160--179, ≥180), different CV risk factors (dyslipidemia, coronary heart disease, diabetes, heart failure (HF), stroke, and kidney disease), and antihypertensive treatments (ACEIs, ARBs, β blockers, CCBs, and diuretics).

Safety Assessments {#Sec6}
------------------

Safety assessments included recording and measurement of all AEs and vital signs in the safety population. The incidence of AEs was recorded at week 4 and 8 of the study period. Each AE was defined by its duration, severity, and relationship to the study drug.

Statistical Analysis {#Sec7}
--------------------

Full analysis set (FAS) included patients with at least one post-baseline efficacy evaluation, and safety set (SS) included patients with at least one post-baseline safety evaluation. The FAS was used for all efficacy analyses. All statistical analyses were performed using SAS^®^ Software version 9.2 (SAS Institute Inc., Cary, NC, USA) at two-sided significance level (*P*) of \<0.05. Demographic and baseline variables were summarized using descriptive statistics, including the mean, standard deviation (SD), median, minimum and maximum values for numeric variables, and the count number and percentage for categorical variables. Paired *t* test, two-way analysis of variance, the Chi square test, and logistic regression were used to analyze efficacy end points. The BP control rates and medication compliance among subgroups was analyzed using Chi square test and Wilcoxon rank-sum test, respectively. AEs were summarized by incidence rates (frequencies and percentages). The efficacy, tolerability, and medication compliance of the SPC evaluated by the investigator and the patient were classified as 'very good', 'good', 'general', and 'not good'.

Results {#Sec8}
=======

Demographic and Baseline Characteristics {#Sec9}
----------------------------------------

A total of 11,422 patients were enrolled for the study, of which 27 patients were excluded for violating GCP, 71 patients did not meet the inclusion criteria, and 63 patients withdrew. Finally, 11,312 patients were included in the FAS, and 11,321 patients in the SS (Fig. [1](#Fig1){ref-type="fig"}). The detailed demographic and baseline characteristics of the patients are presented in Table [1](#Tab1){ref-type="table"}. The mean age of the patients included in the FAS was 58.4 years. Approximately 57% of the patients were male; and 97.1% of the patients belonged to the Han ethnic group. The mean duration of hypertension was 8.3 ± 7.3 years with a mean baseline SBP/DBP value of 159.6/95.6 mmHg. A large proportion of the patients in this study had hypertension without any other CV risk factors (36.9%; *n* = 4,174).Fig. 1Patient flow chart. *BP* blood pressureTable 1Demographic and baseline characteristics of the patients (*n* = 11,312)VariableBaseline valuesAge (years) Mean age (SD)58.4 (13.8) Patients in each group, *n* (%)  \<657,677 (67.9)  65--\<802,863 (25.3)  ≥80746 (6.6)Gender, *n* (%) Male6,456 (57.1)Mean height (SD), cm167.15 (7.8)Mean weight (SD), kg69.18 (11.4)Mean waistline (SD), cm Female82.1 (11.0) Male89.3 (10.4)Ethnicity, *n* (%) Han10,989 (97.1)BMI (kg/m^2^) Mean BMI (SD)24.7 (3.2) Patients in each group, *n* (%)  Underweight (BMI \<19)266 (2.4)  Normal (19 ≤ BMI \< 24)4,449 (39.3)  Overweight (24 ≤ BMI \< 28)5,127 (45.3)  Obese (BMI \>28)1,447 (12.8)Present cardiovascular risk factors/medical history, *n* (%) Dyslipidemia2,702 (23.9) Diabetes1,865 (16.5) CHD1,753 (15.5) HF189 (1.7) Stroke591 (5.2) Kidney disease355 (3.1)BP data (mmHg) Mean baseline SBP159.6 Mean baseline DBP95.6 Patients in each SBP group (*n*, %)  \<140184 (1.6)  140--1595,398 (47.7)  159--1804,816 (42.6)  ≥180914 (8.1)Previous antihypertensive drug classes, *n* (%) β-Blockers903 (7.99) CCBs5,413 (47.90) ACEIs1,728 (15.29) Diuretics321 (2.84) ARB2,853 (25.2) Others82 (0.73) Unknown12 (0.11)*ACEIs* angiotensin-converting enzyme inhibitors, *ARBs* angiotensin-II receptor blockers, *BMI* body mass index, *BP* blood pressure, *CCBs* calcium channel blockers, *CHD* chronic heart disease, *DBP* diastolic blood pressure, *HF* heart failure, *SBP* systolic blood pressure

CCB (47.9%; *n* = 5,413) was the most commonly used monotherapy prior to enrollment, followed by ARB (25.2%; *n* = 2,853) and ACEI (15.3%; *n* = 1,728). The most frequent reasons for switching to SPC included patients unable to achieve BP goals on either the initial or titrated dose of monotherapy (82.0% and 15.0%, respectively), or could not tolerate the original therapy (3.2%).

Efficacy Results {#Sec10}
----------------

### Primary Efficacy {#Sec11}

Val/Aml SPC resulted in a significant reduction in MSSBP by 20.1 mmHg from baseline after 4 weeks (159.6 vs. 139.5 mmHg; *P* \< 0.0001) and 27.1 mmHg after 8 weeks (159.6 vs. 132.5 mmHg; *P* \< 0.0001) of treatment. In addition, a significant reduction in MSDBP by 10.6 mmHg from baseline after 4 weeks (95.6 vs. 85.0 mmHg; *P* \< 0.0001) and 15.2 mmHg after 8 weeks (95.6 vs. 80.4 mmHg; *P* \< 0.0001) of treatment was also noted (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Reduction in mean systolic and diastolic BP after 4 and 8 weeks of valsartan/amlodipine single-pill combination treatment. *\*P* \< 0.0001 vs. baseline. *Error bars* represent standard deviation. *BP* blood pressure, *MSDBP* mean sitting diastolic blood pressure, *MSSBP* mean sitting systolic blood pressure

### Efficacy in Different Subgroups {#Sec12}

The patients were grouped based on their age as \<65 years, 65--\<80 years, and ≥80 years. The mean BP-lowering efficacy of Val/Aml SPC was independent of age (Fig. [3](#Fig3){ref-type="fig"}). Another subgroup analysis based on baseline SBP levels (i.e., SBP \<140, 140--159, 160--179, and ≥180 mmHg) showed significant reductions in MSSBP and MSDBP (*P* \< 0.0001) from baseline in all the baseline SBP groups after 8 weeks of treatment (Fig. [4](#Fig4){ref-type="fig"}). The mean BP reduction increased with an increase in baseline SBP levels.Fig. 3MSSBP and MSDBP reduction in different age groups at week 8. \**P* \< 0.0001 vs. baseline. *Error bars* represent standard deviation. *BP* blood pressure, *MSDBP* mean sitting diastolic blood pressure, *MSSBP* mean sitting systolic blood pressureFig. 4MSSBP and MSDBP reduction in different baseline SBP subgroups at week 8. \**P* \< 0.0001 vs. baseline. *Error bars* represent standard deviation. *BP* blood pressure, *MSDBP* mean sitting diastolic blood pressure, *MSSBP* mean sitting systolic blood pressure, *SBP* systolic blood pressure

The mean reduction in MSSBP from baseline at week 8 in patients treated with Val/Aml from the different antihypertensive monotherapy groups, namely, β blockers, CCBs, ACEIs, diuretics, ARBs, and others, was 28.3, 27.3, 28.1, 27.4, 25.7, and 31.9 mmHg, respectively (Fig. [5](#Fig5){ref-type="fig"}). Reduction in MSDBP was also achieved in the different monotherapy groups after 8 weeks of treatment. As depicted in Fig. [6](#Fig6){ref-type="fig"}, after 8 weeks of SPC treatment, the mean reduction in MSSBP and MSDBP was also observed in the subgroups with different CV risk factors.Fig. 5Mean MSSBP and MSDBP reduction in different monotherapy subgroups at week 8. \**P* \< 0.0001 vs. baseline. *ACEI* ace inhibitor, *ARB* angiotensin receptor blocker, *BP* blood pressure, *CCB* calcium channel blocker, *MSDBP* mean sitting diastolic blood pressure, *MSSBP* mean sitting systolic blood pressureFig. 6MSSBP and MSDBP reduction in subgroups with different cardiovascular risk factors at week 8. \**P* \< 0.0001 vs. baseline. *BP* blood pressure, *CHD* coronary heart disease, *HF* heart failure, *MSDBP* mean sitting diastolic blood pressure, *MSSBP* mean sitting systolic blood pressure, *SBP* systolic blood pressure, *UH* uncomplicated hypertension

### Secondary Efficacy {#Sec13}

A BP control of \<140/90 mmHg was achieved in 76.8% (*n* = 8,692) of patients after 8 weeks of Val/Aml SPC treatment. After 8 weeks of treatment, 98.0% of patients (*n* = 11,084) responded to treatment. Of the 11,312 patients in this study, only 686 (6.1%) patients required add-on therapy at 4 weeks in addition to the Val/Aml SPC treatment. Diuretics were the most frequently used add-on therapy during the study, and 14 patients added 2 additional antihypertensive drugs.

Safety {#Sec14}
------

The SS consisted of 11,321 patients. The most frequently reported AEs were dizziness (0.2%), headache (0.2%), upper respiratory tract infection (0.2%), and edema (0.2%; Table [2](#Tab2){ref-type="table"}). Only three serious AEs were reported during the study; none of them were suspected to be related to the treatment. The tolerability of Val/Aml SPC as evaluated by investigators and patients was quite similar; both evaluations were rated as 'very good' by 63.3% (*n* = 7,170) and 61.3% (*n* = 6,942), respectively. According to the investigators' report, 86.9% (9,787 of 11,266) of the patients had a high adherence rate of 80% or greater while taking the Val/Aml SPC.Table 2Incidence of adverse eventsVariablePatients (*n* = 11,321)Any AE, *n* (%)164 (1.4)Any SAE, *n* (%)3 (\<0.1)AE related to treatment, *n* (%)64 (0.6)SAE related to treatment, *n* (%)0 (0.0)Discontinuations due to AEs, *n* (%)22 (0.2)Most frequent AEs, *n* (%) Dizziness27 (0.2) Headache25 (0.2) Edema19 (0.2) Upper respiratory tract infection18 (0.2) Cough9 (0.1)*AE* adverse event, *SAE* serious adverse event

Discussion {#Sec15}
==========

The present study is the first evidence-based, multicenter, observational real-world study that demonstrates the effectiveness and safety of Val/Aml SPC in reducing BP in a very large number of Chinese hypertensive patients. This study also showed that Val/Aml SPC was well tolerated with a good safety profile, even in patients aged 80 years and older (safety data not presented by age group). The prevalence rate of hypertension is on the rise in China, due to lack of awareness and treatment in addition to inadequate control of the disease \[[@CR7]\]. Various randomized clinical trials (RCTs) have studied the efficacy and safety of Val/Aml SPC in the Chinese population with essential hypertension \[[@CR20], [@CR22], [@CR23]\]. However, most RCTs exclude patients with very high BP and those with a risk of CVD and hence, do not represent findings from actual clinical practice \[[@CR24]\]. In this observational study, patients with SBP ≥180 mmHg, and also those with different CV risk factors were included. Moreover, large observational studies allow the enrollment of an adequate number of patients for subgroup analyses.

Monotherapy is a rational therapeutic approach in patients with mild CV risk or mild BP elevation \[[@CR25]\]. However, in about 70% of patients, it is ineffective in achieving BP goals \[[@CR25]\]. The use of combination therapy having complementary mechanisms of action is more effective than single agents in achieving optimal BP control \[[@CR8], [@CR26]\]. A SPC of Val and Aml has been well tolerated regardless of age, sex, race, or ethnicity \[[@CR27], [@CR28]\]. The safety and efficacy of this combination have also been demonstrated in RCTs of Chinese individuals \[[@CR20], [@CR21]\]. In the present observational study, SPC therapy with Val and Aml resulted in significant reductions in MSSBP and MSDBP from baseline after 8 weeks, consistent with results of randomized controlled studies, including those conducted in Chinese patients \[[@CR20]--[@CR23], [@CR29]--[@CR33]\]. After 8 weeks of treatment, BP control (\<140/90 mmHg) with Val/Aml combination was achieved in approximately 77% of the patients. This is similar to the significant BP control rate (72.7%) observed in a broad spectrum of patients from eight countries (France, Spain, Belgium, Norway, Switzerland, Slovakia, Canada, and The United States) whose BP was initially uncontrolled by monotherapy and who were switched to Val/Aml 160/10 mg or 160/5 mg \[[@CR31]\]. Likewise, another randomized controlled study in a general Asian population reported similar BP control rates (69.2%) in patients treated with Val/Aml SPC (80/5 mg) \[[@CR22]\]. Our findings support the efficacy of the Val/Aml (80/5 mg) SPC in a real-world scenario as well.

SPC therapies improve medication adherence due to reduced pill burden \[[@CR8], [@CR34]\]. In this study, as reported by the patients, more than 85% of patients took 80% or more of the Val/Aml SPC, which could be one of the reasons for improved efficacy. This reinforces the fact that SPC therapy could improve adherence, which is an important factor that influences BP-lowering efficacy of the drug \[[@CR35]\].

Combination therapy has the potential for attenuation of certain drug class---specific AEs \[[@CR2]\]. Val/Aml SPC was well tolerated in this study. There was a low incidence of AEs reported in each treatment phase, with three serious AEs occurring; none of them was suspected to be related to study treatment. A common AE of CCBs is peripheral edema which occurs due to arteriolar dilatation, causing intracapillary hypertension and fluid extravasation \[[@CR36]\]. Despite the use of a CCB (i.e., Aml) in the treatment phase, the incidence of peripheral edema was low with the SPC treatment. This may be attributed to a short observational period, a different dose, or minimization of CCB-induced edema by the ARB (i.e., Val) \[[@CR2]\]. Likewise, a randomized controlled 8-week study of 349 Asian hypertensive patients (predominantly Chinese) treated with Val/Aml 80/5 reported no incidences of peripheral edema \[[@CR22]\] and a similar study of 308 Asian patients reported a 1.3% incidence \[[@CR23]\].

In this study, treatment was effective regardless of baseline BP, comorbidities, monotherapy, or age. Elderly patients with hypertension are at an increased risk of adverse CVD outcomes such as HF and stroke \[[@CR37]\]. Therefore, effective lowering of BP in the elderly is clinically very important. Clinical trials very rarely recruit from the elderly population, however, in the present observational study, a sufficient number of elderly patients over 80 years of age (*n* = 746) were included. In this study, after 8 weeks of Val/Aml SPC treatment reported significant reductions in BP in elderly patients. A recent RCT involving 61 Chinese elderly patients has also shown the efficacy of the Val/Aml combination therapy in lowering BP in the elderly population \[[@CR38]\].

A limitation of the study design was the addition of Val/Aml onto other antihypertensive monotherapies at week 0 or another antihypertensive drug added onto Val/Aml at week 4 (when BP cannot be controlled), which might have contributed to increased efficacy of the treatment, although the impact of this has not been determined. This study observed a low incidence of AEs compared to several randomized trials with the same SPC, which may be attributed to the shorter treatment period of 8-weeks \[[@CR13], [@CR14]\]. Alternatively, it is possible that inadequate communication between the investigator and the patient could have resulted in non-recording of events and hence the low incidence of AEs.

Conclusion {#Sec16}
==========

In conclusion, the findings from the first real-world observational study in Chinese hypertensive patients confirm the effectiveness and safety of using SPC Val and Aml in a large population. By initiating treatment with this combination, significant and early reductions in both MSSBP and MSDBP were achieved, which enabled a large proportion of the patients to reach a BP goal of 140/90 mmHg in 8 weeks. The outcomes of this SPC were found to be safe and tolerable with low incidences of AEs in a wide range of Chinese patients with uncontrolled BP on monotherapy. Additional studies of longer durations are necessary to investigate the potential clinical benefits of this SPC on organ protection and CV outcome improvement.
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